TranslationalResearch

Researchers at the University of Turku have identified a novel biomarker that may revolutionize how clinicians assess the progression and severity of multiple sclerosis (MS), a chronic autoimmune disease of the central nervous system. The groundbreaking study, published in Nature Medicine, offers promising new directions for both targeted treatment and faster development of therapeutic drugs—particularly for progressive MS, which remains one of the most challenging forms of the disease to treat.

At the prestigious American Association for Cancer Research (AACR) Annual Meeting 2025, researchers from The University of Texas MD Anderson Cancer Center unveiled promising results from several pioneering clinical trials that could redefine treatment paradigms across multiple cancer types. The presentations, covering personalized vaccines, metastasis-directed radiation therapy, and engineered exosome therapeutics, signal major advances in personalized oncology and immunotherapy.